drugset / Trial / NCT01137006
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FLANVOTUMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | FLANVOTUMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | FLANVOTUMAB | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | FLANVOTUMAB | Monoclonal antibody | 30 mg/kg | Intravenous |